Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors inside the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements examine identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availa... https://davidp974oss6.eveowiki.com/user